Domperidone, a novel and safe gastrokinetic anti-nauseant for the treatment of dyspepsia and vomiting.
The new potent anti-nauseant 5-chloro-1-(1p[3-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-propyl]-4-piperidinyl)-1.3-dihydro-2H-benzimidazol-2-one (domperidone), which in contrast to available anti-emetics does not provoke extrapyramidal or adrenolytic adverse effects, also enhances gastric emptying motility. Controlled clinical trials have confirmed its prokinetic effects on the stomach and its lack of side-effects, even at high doses. This anti-nauseant appears to be a safe and effective treatment for patients, both adults and children, with dyspepsia or vomiting.
D000818:Animals; D000932:Antiemetics / Q000494:pharmacology* / Q000627:therapeutic use; D001562:Benzimidazoles / Q000494:pharmacology* / Q000627:therapeutic use; D004285:Dogs; D004415:Dyspepsia / Q000188:drug therapy*; D005746:Gastric Emptying / Q000187:drug effects; D005769:Gastrointestinal Motility / Q000187:drug effects; D006168:Guinea Pigs; D006801:Humans; D066298:In Vitro Techniques; D010880:Piperidines / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D014839:Vomiting / Q000188:drug therapy*
D000932:Antiemetics; D001562:Benzimidazoles; D010880:Piperidines